Novo Nordisk’s Wegovy and copyright, each powered by semaglutide, have revolutionized obesity therapy by way of unprecedented weight loss final results. In Oct 2024, Novo Nordisk published a analyze on scientific journal Character about a novel glucose-delicate insulin NNC2215 that coul